Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | CDA | P32320 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADA | P00813 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305941 | 1.00 | KDM4E (0.52) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL11123748 | 0.90 | KDM4E (0.52) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL30195858 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL1001272 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL8371824 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL31265252 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL1319619 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL8368934 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL8047049 | 0.83 | ADORA3 (0.56) | KDM4EPKMALDH1A1TP53HTT | |
| SCHEMBL4215253 | 0.82 | ADORA3 (0.55) | KDM4EPKMALDH1A1TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0043722-B1 | BETA-D-ARABINOFURANOSYLIMIDAZO (4,5-C)PYRIDINE COMPOUNDS AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1984-05-23 | — | — | EP | claimed |
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-0043722-B1 | BETA-D-ARABINOFURANOSYLIMIDAZO (4,5-C)PYRIDINE COMPOUNDS AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| EP-0043722-B1 | BETA-D-ARABINOFURANOSYLIMIDAZO (4,5-C)PYRIDINE COMPOUNDS AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4315000-A | β-D-Arabinofuranosylimidazo(4,5-c)pyridine compounds and methods for their production | WARNER-LAMBERT COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| US-4315000-A | β-D-Arabinofuranosylimidazo(4,5-c)pyridine compounds and methods for their production | WARNER-LAMBERT COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| US-4315000-A | β-D-Arabinofuranosylimidazo(4,5-c)pyridine compounds and methods for their production | WARNER-LAMBERT COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| EP-0043722-A1 | Beta-D-Arabinofuranosylimidazo (4,5-c)pyridine compounds and processes for their production | WARNER-LAMBERT COMPANY (US) | 1982-01-13 | — | — | EP | disclosed |
| EP-0043722-A1 | Beta-D-Arabinofuranosylimidazo (4,5-c)pyridine compounds and processes for their production | WARNER-LAMBERT COMPANY (US) | 1982-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | REV1, NSUN2, ORC3 | KDM4E 4781/4885PKM 3163/4885ALDH1A1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.